VILLA CARLOTTA (Topic Fora)











Attenzione: apre in una nuova finestra.

Topic Forum 1 Sunday, September 2, 8:00 – 9:45 am
The LES following surgery
Chairs: I. Braghetto (Santiago) – Lee (Omaha)
Discussant: M. Loviscek (Buenos Aires)

  • What pre-operative testing provides most optimal information on esophageal  function prior to ARS? C.P. Gyawali (St Louis)

Following antireflux procedures:

  • The endoscopic characteristics of the EGJ  following different types of fundoplication. B.A. Jobe (Pittsburgh)
  • The radiologic characteristics of antireflux valves following surgery. D. Cavadas (Buenos Aires)
  • Are distensibility techniques useful  peri-operatively in upper GI surgery? J. Lenglinger (Vienna)
  • Which is the best method to evaluate the LES after surgery? S.Szachnowicz (Sao Paulo)
  • Is there correlation with the endoscopic findings? A. Csendes (Santiago)           
  • Do postoperative radiological findings correlate with manometric findings? R.P. Tatum (Seattle)
  • Postoperative manometry and 24h pH monitoring. G.M. Del Genio (Naples)
  • What happens with LES following antireflux surgery in long segment Barrett esophagus ? A. Csendes (Santiago)
  • The magnetic sphincter. L. Bonavina (Milan)
  • Have Toupet or Dor fundoplication a significant effect on increase of LES? G.M. Del Genio (Naples)

Following other procedures:

  • LES after distal partial gastrectomy O. Korn (Santiago)
  • LES after sleeve gastrectomy I. Braghetto (Santiago)
  • LES after gastric bypass. S. Szachnowicz (Sao Paulo)
  • LES after failed myotomy for achalasia: fibrosis or incomplete myotomy? A. Badaloni (Buenos Aires)
  • Is there a role for HRM in the evaluation of post-gastric banding symptoms? M. Loviscek(Buenos Aires)

Topic Forum 2 Sunday, September 2, 10:15 am - 12:00 pm
Outcomes in esophageal surgery
Chairs: B. Gayet (Paris) – R.P. Tatum (Seattle)
Discussant: M.S. Allen (Rochester, MN)

  • Paraesophagael Hernia: watchful waiting versus elective repair? R.P. Tatum (Seattle)
  • Is bioprosthetic mesh superior to synthetic mesh when used to repair a para-esophageal hiatus hernia? E. Figueredo (Seattle)
  • Esophageal lengthening versus no esophageal lengthening? J.J. Lam (Pittsburgh)
  • Fundoplication versus no fundoplication in para-esophageal hernia repair L.L. Swanström (Portland)
  • Antireflux surgery for the management of extra-esophageal reflux disease
  • Endoluminal antireflux techniques C. Schuhmacher (Munich)
  • Outcomes after endoscopic antireflux procedures L.L. Swanström (Portland)
  • Who is the ideal patient for the transoral incisionless fundoplication (TIF) procedure? R.P. Petersen (Seattle)
  • Options for repair (redo fundoplication, Roux-en-Y, esophagectomy) M. Loviscek (Buenos Aires)
  • Are outcomes of fundoplication in the obese patient population equivalent to those in the non-obese? I. Braghetto (Santiago)
  • Should Roux-en-Y gastric bypass the primary option for treatment of GERD in the morbidly obese? D. Nocca (Montpellier)
  • Outcomes  of revisional antireflux surgery– Surgical and quality of life E.B. Wassenaar (Seattle)
  • Does the routine use of intra-operative esophageal manometry lead to better patient outcomes in antireflux surgery? G.M. Del Genio (Naples)
  • What is the role of HRM in the evaluation of factors responsible for failure of fundoplication? R.V. Soares (Seattle)

Topic Forum 3 Sunday, September 2, 2:30 – 4:15  pm
Imaging
Chairs: P. Pokieser (Vienna) – M.S. Levine (Philadelphia)
Discussant: C.L. Canon (Birmingham, AL)

  • How should the radiologist test for gastroesophageal reflux at fluoroscopy? What is the value of the water-siphon test? C.L. Canon (Birmingham, AL)
  • What is the importance of hiatal hernias for GERD and how are hernias imaged on barium studies? C.L. Canon
  • What are the morphologic findings of reflux esophagitis on double-contrast esophagography and what is the value of this examination? M.S. Levine (Philadelphia)
  • How is scarring (including peptic strictures and rings) from reflux esophagitis manifested on barium esophagography? M.S. Levine
  • Are there characteristic pharyngeal findings on barium studies in patients with reflux disease and what is the value of videofluoroscopy in these patients? P. Pokieser (Vienna)
  • Is there a characteristic form of esophageal dysmotility on barium esophagography in patients with reflux disease? M.S. Levine
  • What are the imaging findings after anti-reflux surgery? C.P. Canon
  • Is there a benefit of recent developments for staging of esophageal cancer with multislice CT? P. Pokieser (Vienna)
  • Endoflip and videofluoroscopy: are the newcomer and the oldtimer complementary or competitive tests? J. Lenglinger (Vienna)

Topic Forum 4 Sunday, September 2, 4:30 - 6:15 pm
Innovative technologies
Chairs: S. Hamdy (Manchester) – R. Van Hillegersberg (Utrecht)
Discussant: K. Bitar (Winston Salem)
Secretary: P. van der Sluijs (Utrecht)

  • Can the smart-pill wireless motility capsule provide complementary clinical information in patients with gastro-esophageal disease? A.R. Hobson (London)                                  
  • What is the role of high resolution endoscopy in esophageal disorders? H. Neumann (Erlangen)
  • How much further can HRM take us in understanding motility disorders? A. Bansal (Kansas City)
  • Can MRI be used to assess mucosal/muscle based abnormalities in the esophagus? I. Lips (Utrecht)
  • What is the role of the Functional Lumen Imaging Probe? B. McMahon (Dublin)
  • What is the role of RF ablation of early esophageal cancer. M. Häfner (Vienna)
  • Robotic surgery and navigation in esophageal cancer and reflux disease. R. Van Hillegersberg (Utrecht)                                                                                              
  • Brain stimulation and the esophagus. S. Hamdy (Manchester)
  • Diffuse Noxious Inhibitory Control  induction and esophageal  EEG C. Brock (Aalborg)
  • Evoked potentials and the esophagus – Clinical application. A. Hobson (London)
  • Can GERD be treated by electro-stimulation? J. Ruurda (Utrecht)
  • What is the role of POEMS? H. Inoue (Yokohama)
  • What is the role of biological scaffolds in esophageal reconstruction? K. Bitar (Winston Salem)
  • Can genetic profiling be used to predict the outcome of esophageal cancer therapy? C.J. Peters (Cambridge)

Topic Forum 5 Monday, September 3, 8:15 - 10:00 am
Natural orifice surgery

Chairs: H. Inoue (Yokohama) – L.L. Swanström (Portland)
Discussant: S. Perretta (Strasbourg)

  • Flexible mediastinoscopy for cancer staging L.L. Swanström (Portland)    
  • Endoscopic management of esophageal perforations. K.L. Goh (Kuala Lumpur)
  • NOTES for Achalasia (POEM) H. Inoue (Yokohama)
  • POEM for spastic motility disorders. E.B. Wassenaar (Seattle)
  • Trans-esophageal procedures  S. Perretta (Strasbourg)
  • Reaching beyond NOTES from endoscopic to cellular therapy: endoscopic injection of muscle-derived cells to augment gut smooth muscle sphincter function A. Nieponice (Buenos Aires)
  • Skinning esophagectomy for superficial esophageal tumors: implication for a novel  therapeutical approach A. Nieponice (Buenos Aires)
  • Noninvasive endoscopic sentinel node MRI based identification for esophageal cancer S. Perretta (Strasbourg)
  • Novel esophageal anastomosis and reconstruction techniques J. Wall (Palo Alto)
  • Can we truly improve esophageal functional surgery? J.J. Lamb (Pittsburgh)
  • Introducing POEM into routine clinical practice: are there yet? L.L. Swanström (Portland)
  • Per oral endoscopic resection of esophageal leiomyomas H. Inoue (Yokohama)

Topic Forum 6 Monday, September 3, 10:15 am - 12:00 pm
Posters – Oral presentation

Chairs:
R.W. McCallum (El Paso) – M. Upton (Seattle)
Panel: J.G. Brasseur (University Park) – J.O. Clarke (Baltimore) – X. Luke Chen (Durham) – F. Pace (Bergamo) -  M. Schiesser (Zurich)

The program of this session will be determined on Monday September 3 following the selection by the Jury. The names of the Authors of the 12 Posters selected for oral presentation will be posted at the Registration Desk on Monday September 3, at 7:30 am. Don’t forget to drop off your slides at the Slide Center.

Topic Forum 7 Monday, September 3, 2:30 – 4:15 pm
Video Session
Chairs: S. Puntambekar (Pune) – D. Nocca (Montpellier)

  • Transgastric treatment of gastric cancer using single port B. Gayet (Paris)
  • Laparoscopic gastric bypass R. Caiazzo (Lille)
  • Laparoscopic sleeve gastrectomy M. Poussier (Montpellier)      
  • The sleeve gastrectomy one port (LESS) G. Pourcher (Paris)
  • Laparoscopic gastrectomy for cancer M. Gualterotti (Naples)
  • Laparoscopic treatment of GERD G.M. Del Genio (Naples)     
  • Extended esophagectomy for cancer by laparoscopic and thoracoscopic approach in prone position F. Lacerda Croider (Barretos)


Topic Forum 8 Monday, September 3, 4:30 - 6:15 pm
Molecular Biology
Chairs: G. Nardone (Naples) – S. Krishnadath (Amsterdam)
Discussant: R.F. Souza (Dallas)
Secretart: A. Pacha (Amsterdam)

  • Is malignant degeneration of Barrett's esophagus a clonal disease? A. Pacha (Amsterdam)
  • Is there a model for  Barrett’s esophagus to predict progression to esophageal adenocarcinoma? K. Parikh (Amsterdam)
  • Is there a reliable prognostic or diagnostic biomarker test to predict progression of Barrett’s esophagus? A. Pacha (Amsterdam)
  • What genes are involved in the development of esophageal squamous epithelium during embryogenesis and at birth? N.S. Buttar (Rochester, MN)
  • What is the role of CDX-2 in the development of the gut and esophagus Barrett’s esophagus? D. Tosh (Bath)
  • Which morphogenes play a role in Barrett’s esophagus? S. Krishnadath (Amsterdam)
  • Can the in-vitro model of Barrett’s epithelium to EAC be utilized for chemoprevention studies? K. Das (New Brunswick)
  • Which in vivo models do we have for testing chemopreventive drugs for Barrett’s esophagus? N.S. Buttar (Rochester, MN)
  • Is the surgical animal model for Barrett’s esophagus validated at the molecular level? M.K. Gibson (Pittsburgh)
  • What are the potential  chemopreventive targets in Barrett’s esophagus? N.S. Buttar (Rochester, MN)
  • Which existing drugs  can be used for chemoprevention of Barrett’s esophagus? L.X. Chen (Durham)
  • What junctial proteins predispose patients with reflux to Barrett’s esophagus and esophageal adenocarcinoma? R.C. Orlando (Chapel Hill)

Topic Forum 9 Tuesday, September 4, 7:45 – 9:30 am
Drugs for esophageal disease
Limitations of the current compounds – Perspectives for the future

Chairs: C. Scarpignato (Parma) – R. Hunt (Hamilton)
Discussant: F. Di Mario (Treviso)

  • What are the shortcomings of the delayed-release PPIs (DR-PPIs)? R.H. Hunt (Hamilton)
  • Can the shortcomings of PPIs be attributed to poor response in reflux patients? R.H. Hunt (Hamilton)
  • How does symptom control compare with healing in RCTs of reflux esophagitis? F. Pace (Milan)
  • What is the acid suppression profile of twice daily DR-PPIs: how much acid is left? R.H. Hunt (Hamilton)
  • What is the response of reflux esophagitis to twice daily DR-PPIs? F. Pace (Milan)
  • The use of PPis after laparoscopic fundoplication: failure of surgery or failure of physician? C. Scarpignato (Parma)
  • Immediate-release PPIs: do they suppress NAB and improve nighttime symptom control? W.W. Chan (Boston)
  • Acid suppression with extended-release formulations of current PPIs: what is the real therapeutic gain?  F. Di Mario (Treviso)
  • Novel long-lasting PPIs: could they address the unmet clinical needs in GERD? C. Scarpignato (Parma)
  • Reflux inhibitors: pharmacological failure or flawed concept? F. Zerbib (Bordeaux)
  • Novel prokinetic compounds: do they still have a role in the treatment of GERD? C. Blandizzi (Pisa)

Topic Forum 10 Tuesday, September 4, 9:40 – 11:25 am
Neurogenic dysphagia - Oro-pharyngeal dysphagia

Chairs:
P. Clavé (Mataro) – B. Martin-Harris (Charleston)
Discussant:
P. Belafsky (Los Angeles)
Secretary: O. Ortega Fernandez (Mataro)

  • What is dysphagia? D.O. Castell (Charleston)
  • What outcome measures matter: clinical, instrumental, nutrition, quality of life? P. Clavé (Mataro)
  • Can we predict models of recovery of oropharyngeal dysphagia based on diagnosis? B. Martin-Harris (Charleston)
  • Videofluoroscopy and FEES are used as assessments of oropharyngeal swallowing function: do they miss esophageal impairment? P. Pokieser (Vienna)
  • What are the properties of an optimal stimulus for elicitation of oropharyngeal and esophageal swallowing? P. Clavé (Mataro)
  • What is the relationship between esophageal muscle function and perception of dysphagia? D. Sifrim (London)
  • How does the UES open in the absence of suprahyoid muscle function? R. Shaker (Milwaukee)
  • Are there any imaging criteria for myotomy of the UES or botulinum toxin injection in patients with neurologic swallowing impairment? P. Pokieser (Vienna)
  • What is the value of crico-pharyngeal myotomy? What are the histological findings? P. Belafsky (Los Angeles)
  • Does pharyngeal peristalsis exist? What are the underlying mechanism(s) and implications for treatment? B. Martin-Harris (Charleston)
  • Patients with specific oro-pharyngeal swallowing impairment are sometimes treated by altering head positioning and/or bolus consistency: what are the mechanical mechanisms by which these maneuvers alter function in the oropharynx? A. Ouyang (Hershey)
  • In patients with neurogenic  dysphagia, what medications can be considered as protective against aspiration pneumonia? P.Clavé (Mataro)
  • Does respiratory – swallow coordination contribute to dysphagia and if so, can patterns of coordination be trained? B. Martin-Harris (Charleston)
  • Can esophageal musculature be trained? A. Ouyang (Hershey)
  • Do surgical interventions restore critical components of oro-pharyngeal swallowing function? P. Belafsky (Los Angeles)